Custom Monoclonal Antibody
Development & Scale-Up Services
From antigen design and mouse immunization to high-throughput hybridoma screening and bioreactor scale-up. Engineered specifically for IVD rapid test manufacturers, high-sensitivity ELISA developers, and biopharma researchers.
Precision Monoclonal Antibody Development
SMD Life Sciences offers high-affinity murine monoclonal antibody development designed from the ground up for diagnostic and therapeutic diagnostic applications. Whether you require antibodies for a novel infectious biomarker, a steroid hormone, or a critical cardiac protein, our hybridoma platform delivers stable, high-affinity clones with validated sensitivity and lot-to-lot reproducibility.
High analytical sensitivity and stability across diverse sample matrices (whole blood, serum, plasma, urine).
Simultaneous validation of capture and detection antibody pairs on colloidal gold rapid test strips and ELISA plates.
4-Phase Milestone Development Architecture
You only pay for milestones as deliverables are verified and approved by your scientific team.
Antigen Preparation & Immunization
Splenic Fusion & High-Throughput Screening
Single-Cell Subcloning & Master Banking
Pilot In-Vitro Production & Protein A/G Purification
Matched Antibody Pair Development for Rapid Tests & ELISA
Unlike academic hybridoma services that deliver antibodies binding random epitopes, we evaluate clones in matrix pairs directly on your chosen detection platform. We identify non-competing epitope pairs where one antibody acts as the solid-phase capture agent (membrane coat) and the second acts as the reporter conjugate (colloidal gold, latex, or fluorescent nanoparticles).
Rigorous competitive cross-blocking assay confirms both antibodies bind simultaneously.
Screening for high conjugation stability at 40nm gold pH 8.0–9.0 without passive precipitation.
Elimination of heterophilic antibody interference and human anti-mouse antibody (HAMA) cross-binding.
Why Choose SMD Life Sciences for Custom mAbs?
Compare our domestic Bangalore facility advantages against overseas vendors and academic labs.
| Evaluation Parameter | SMD Life Sciences | Overseas / Traditional Vendors |
|---|---|---|
| Intellectual Property & Clone Ownership | 100% Client Ownership (Zero reach-through royalties, full commercial freedom) | Often retain partial rights or demand licensing fees for commercial diagnostic use |
| Serum Titer Milestone Guarantee | Guaranteed ELISA titer >= 1:128,000 before proceeding to fusion stage | Proceed blindly to fusion regardless of immune response quality |
| IVD Matched Pair Screening Capability | Simultaneous pairing matrix on Lateral Flow strips and 96-well Sandwich ELISA plates | Only perform standard indirect ELISA, leaving pair optimization to the client |
| Facility & Cold-Chain Logistics | Bangalore Cleanroom Lab & 24–48h dry ice express shipping across India | Overseas shipments vulnerable to customs holds, dry ice sublimation, and degradation |
| Technical Consultation & Customization | Direct one-on-one scientific milestone review meetings with project immunologists | Impersonal ticketing systems with standard non-negotiable protocols |
Frequently Asked Technical Questions
What is the typical turnaround time for custom monoclonal antibody development?
The complete 4-phase hybridoma monoclonal antibody development protocol typically takes 12 to 16 weeks. Fast-track express immunization protocols can yield primary fusion candidates in as early as 9 to 10 weeks.
Who owns the intellectual property (IP) and hybridoma clones?
100% of the intellectual property, parental hybridoma cell lines, sequence data, and generated antibodies belong exclusively to the client. SMD Life Sciences operates on a fee-for-service model with zero reach-through royalties.
Can you develop matched antibody pairs for lateral flow rapid tests and sandwich ELISA?
Yes. We specialize in matched antibody pair development specifically designed for IVD assay platforms. Clones are cross-screened simultaneously as capture antibodies (solid phase) and detection antibodies (colloidal gold/HRP/fluorescent conjugate) to ensure zero epitope competition and high analytical sensitivity.
What happens if the mouse serum titer is insufficient at Phase 1?
We guarantee an ELISA titer of at least 1:128,000 against the target antigen before proceeding to cell fusion. If the titer does not meet benchmark criteria, booster regimens are extended or the project is halted with zero financial liability for subsequent unperformed phases.
Project Inquiry Form
Tell us about your diagnostic or R&D requirements
Bangalore R&D Facility
Electronic City Phase 1, Bangalore
